Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection.
Hu Y, Paris S, Sahoo N, Bertolet G, Wang Q, Wang Q, Barsoumian HB, Da Silva J, Huang A, Doss DJ, Pollock DP, Hsu E, Selene N, Leyton CSK, Voss TA, Masrorpour F, Ganjoo S, Leuschner C, Pietz JT, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. Hu Y, et al. Among authors: masrorpour f. JCI Insight. 2023 Jun 22;8(12):e167749. doi: 10.1172/jci.insight.167749. JCI Insight. 2023. PMID: 37345658 Free PMC article.
Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects.
Hu Y, Paris S, Barsoumian H, Abana CO, He K, Wasley M, Younes AI, Masrorpour F, Chen D, Yang L, Dunn JD, Zhang J, Gandhi S, Nguyen QN, Cortez MA, Welsh J. Hu Y, et al. Among authors: masrorpour f. Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3):647-657. doi: 10.1016/j.ijrobp.2021.06.041. Epub 2021 Jul 6. Int J Radiat Oncol Biol Phys. 2021. PMID: 34242713
A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model.
Hu Y, Paris S, Barsoumian H, Abana CO, He K, Sezen D, Wasley M, Masrorpour F, Chen D, Yang L, Dunn JD, Gandhi S, Nguyen QN, Cortez MA, Welsh JW. Hu Y, et al. Among authors: masrorpour f. J Nanobiotechnology. 2021 Dec 11;19(1):416. doi: 10.1186/s12951-021-01163-1. J Nanobiotechnology. 2021. PMID: 34895262 Free PMC article.
Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer.
Hu Y, Paris S, Bertolet G, Barsoumian HB, He K, Sezen D, Chen D, Wasley M, Silva JD, Mitchell JA, Voss TA, Masrorpour F, Leyton CK, Yang L, Leuschner C, Puebla-Osorio N, Gandhi S, Nguyen QN, Cortez MA, Welsh JW. Hu Y, et al. Among authors: masrorpour f. J Nanobiotechnology. 2022 Sep 19;20(1):417. doi: 10.1186/s12951-022-01621-4. J Nanobiotechnology. 2022. PMID: 36123677 Free PMC article.
Pulsed radiotherapy to mitigate high tumor burden and generate immune memory.
Sezen D, Barsoumian HB, He K, Hu Y, Wang Q, Abana CO, Puebla-Osorio N, Hsu EY, Wasley M, Masrorpour F, Wang J, Cortez MA, Welsh JW. Sezen D, et al. Among authors: masrorpour f. Front Immunol. 2022 Oct 6;13:984318. doi: 10.3389/fimmu.2022.984318. eCollection 2022. Front Immunol. 2022. PMID: 36275767 Free PMC article.
NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model.
Hu Y, Paris S, Bertolet G, Barsoumian HB, Wang Q, Da Silva J, Patel NB, Nguyen N, Doss DJ, Huang A, Hsu E, Leyton CSK, Voss TA, Masrorpour F, Leuschner C, Pietz JT, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. Hu Y, et al. Among authors: masrorpour f. Front Immunol. 2022 Nov 3;13:1022011. doi: 10.3389/fimmu.2022.1022011. eCollection 2022. Front Immunol. 2022. PMID: 36405757 Free PMC article.
Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer.
He K, Barsoumian HB, Puebla-Osorio N, Hu Y, Sezen D, Wasley MD, Bertolet G, Zhang J, Leuschner C, Yang L, Kettlun Leyton CS, Fowlkes NW, Green MM, Hettrick L, Chen D, Masrorpour F, Gu M, Maazi H, Revenko AS, Cortez MA, Welsh JW. He K, et al. Among authors: masrorpour f. Cancer Immunol Res. 2023 Apr 3;11(4):486-500. doi: 10.1158/2326-6066.CIR-22-0547. Cancer Immunol Res. 2023. PMID: 36700864 Free PMC article.
Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma.
Barsoumian HB, Ramapriyan R, Younes AI, Caetano MS, Menon H, Comeaux NI, Cushman TR, Schoenhals JE, Cadena AP, Reilly TP, Chen D, Masrorpour F, Li A, Hong DS, Diab A, Nguyen QN, Glitza I, Ferrarotto R, Chun SG, Cortez MA, Welsh J. Barsoumian HB, et al. Among authors: masrorpour f. J Immunother Cancer. 2020 Oct;8(2):e000537. doi: 10.1136/jitc-2020-000537. J Immunother Cancer. 2020. PMID: 33106386 Free PMC article.
Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity.
Younes AI, Barsoumian HB, Sezen D, Verma V, Patel R, Wasley M, Hu Y, Dunn JD, He K, Chen D, Menon H, Masrorpour F, Gu M, Yang L, Puebla-Osorio N, Cortez MA, Welsh JW. Younes AI, et al. Among authors: masrorpour f. Transl Oncol. 2021 Feb;14(2):100983. doi: 10.1016/j.tranon.2020.100983. Epub 2020 Dec 16. Transl Oncol. 2021. PMID: 33340886 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 34700585
18 results